AU2020360413A1 - Methods of treating conditions related to the S1P1 receptor - Google Patents

Methods of treating conditions related to the S1P1 receptor Download PDF

Info

Publication number
AU2020360413A1
AU2020360413A1 AU2020360413A AU2020360413A AU2020360413A1 AU 2020360413 A1 AU2020360413 A1 AU 2020360413A1 AU 2020360413 A AU2020360413 A AU 2020360413A AU 2020360413 A AU2020360413 A AU 2020360413A AU 2020360413 A1 AU2020360413 A1 AU 2020360413A1
Authority
AU
Australia
Prior art keywords
compound
individual
disease
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020360413A
Other languages
English (en)
Other versions
AU2020360413A8 (en
Inventor
Lisette Marie ACEVEDO
Thai Curtis NGUYEN-CLEARY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of AU2020360413A1 publication Critical patent/AU2020360413A1/en
Publication of AU2020360413A8 publication Critical patent/AU2020360413A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AU2020360413A 2019-10-01 2020-09-30 Methods of treating conditions related to the S1P1 receptor Abandoned AU2020360413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
AU2020360413A1 true AU2020360413A1 (en) 2022-04-14
AU2020360413A8 AU2020360413A8 (en) 2022-04-21

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020360413A Abandoned AU2020360413A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the S1P1 receptor

Country Status (12)

Country Link
US (1) US20220347158A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037678A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022550458A (cg-RX-API-DMAC7.html)
KR (1) KR20220074913A (cg-RX-API-DMAC7.html)
CN (2) CN119280227A (cg-RX-API-DMAC7.html)
AU (1) AU2020360413A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005999A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156182A1 (cg-RX-API-DMAC7.html)
IL (1) IL291654A (cg-RX-API-DMAC7.html)
MX (1) MX2022003982A (cg-RX-API-DMAC7.html)
TW (1) TW202114656A (cg-RX-API-DMAC7.html)
WO (1) WO2021067506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135506A1 (en) 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) * 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) * 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) * 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법

Also Published As

Publication number Publication date
US20220347158A1 (en) 2022-11-03
MX2022003982A (es) 2022-07-12
KR20220074913A (ko) 2022-06-03
WO2021067506A1 (en) 2021-04-08
JP2022550458A (ja) 2022-12-01
TW202114656A (zh) 2021-04-16
CA3156182A1 (en) 2021-04-08
AU2020360413A8 (en) 2022-04-21
CN119280227A (zh) 2025-01-10
EP4037678A4 (en) 2023-11-29
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
JP7219732B2 (ja) S1p1受容体に関連する状態の処置方法
KR20160148050A (ko) 라퀴니모드를 이용한 크론병의 치료
JP2017200926A (ja) 第一選択の抗TNEα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP2025024035A (ja) S1p1受容体に関連する状態を治療する方法
EP4240349A1 (en) Methods of treating conditions related to the s1p1 receptor
WO2021067506A1 (en) Methods of treating conditions related to the s1p1 receptor
WO2021163355A1 (en) Formulations and methods of treating conditions related to the s1p1 receptor
US20240277662A1 (en) Administration of a Compound to Individuals with Hepatic Impairment
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
TWI855501B (zh) 治療方法
HK40116740A (en) Methods of treating conditions related to the s1p1 receptor
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
HK40109901A (en) Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
HK40116488A (en) Methods of treating conditions related to the s1p1 receptor
WO2026043678A1 (en) Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy
AU2023203085A1 (en) Methods of treating conditions related to the S1P1 receptor
WO2025184133A1 (en) Methods of treating chronic graft versus host disease with belumosudil after ceasing administration of ruxolitinib
WO2021234430A1 (en) Modified release dosage form comprising vildagliptin and process for manufacturing the same

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 15 , PAGE(S) 2215 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ARENA PHARMACEUTICALS, INC., APPLICATION NO. 2020360413, UNDER INID (54) CORRECT THE TITLE TO READ METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted